Down-regulated Hormonally Controlled Cycles for Vitrification-warmed Blastocyst Transfers

• Register: ClinicalTrials.gov
• Last refreshed on: 13 June 2016
• Main ID: NCT02238431
• Date of registration: 05/09/2014
• Prospective Registration: Yes
• Primary sponsor: Antalya IVF
• Public title: Down-regulated Hormonally Controlled Cycles for Vitrification-warmed Blastocyst Transfers
• Scientific title: Down-regulated Hormonally Controlled Cycles for Vitrification-warmed Blastocyst Transfers: Reduces Time to Transfer and Cycle Cancellation
• Date of first enrolment: December 2014
• Target sample size: 0
• Recruitment status: Withdrawn
• URL: https://clinicaltrials.gov/show/NCT02238431
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
• Phase: N/A

Countries of recruitment

Turkey

Key inclusion & exclusion criteria

Inclusion Criteria:

- If patients have >2 blastocysts vitrified

Exclusion Criteria:

- All patients not willing to participate in the study

- Patients with any known adverse reaction to one or the other of the drugs prescribed

- All patients that have no surviving blastocysts for transfer



Age minimum: 20 Years
Age maximum: 42 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Pregnancy

Intervention(s)

Other: Natural

Drug: Lucrin depot

Drug: OCP

Primary Outcome(s)

Cycle cancellation [Time Frame: On day 14 of estrogen supplementation]

Secondary Outcome(s)

Ongoing pregnancy rate [Time Frame: 20 weeks of gestation]

Secondary ID(s)

FET cycle cancellation

Lucrin depot FET cycle

Source(s) of Monetary Support

Please refer to primary and secondary sponsors